Cite
HARVARD Citation
Ludwig, H. et al. (2021). Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial). EJHaem. 2 (1), pp. 99-103. [Online].